Search results for "E-F"

showing 10 items of 836 documents

Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis.

1998

Objective This study compares the results of liver transplantation (LTx) and liver resection (LR) for hepatocellular carcinoma (HCC) to test the widespread hypothesis that LTx is the preferable approach for small HCCs. Summary Background Data With respect to scarcity of donor organs and poor results, LTxs for large HCCs are obsolete. Small HCC transplantations have been reported to result in an excellent survival rate. However, the data of comparative studies are controversial. Methods Patients who were treated curatively by LTx (n = 50) or LR (n = 52) for HCC were included in this retrospective study. Survival and freedom from recurrence were analyzed. Patients were stratified according to…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationGastroenterologyDisease-Free SurvivalResectionText miningInternal medicinemedicineHepatectomyHumansSurvival rateAgedRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateHepatocellular carcinomaSurgeryFemaleNeoplasm Recurrence LocalbusinessResearch Article
researchProduct

Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial.

2020

Background Neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer carries a high risk of adverse effects. The aim of this study was to examine the selective application of nCRT based on patient risk profile, as determined by MRI, to find the optimal range between undertreatment and overtreatment. Study Design In this prospective multicenter observational study, nCRT before total mesorectal excision (TME) was indicated in high-risk patients with involved or threatened mesorectal fascia (≤1 mm), or cT4 or cT3 carcinomas of the lower rectal third. All other patients received primary surgery. Results Of the 1,093 patients, 878 (80.3%) were treated according to the protocol, 526 pat…

AdultMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentMedical OveruseDisease-Free Survival03 medical and health sciences0302 clinical medicinemedicineHumansProspective StudiesStage (cooking)Adverse effectPathologicalAgedNeoplasm StagingAged 80 and overProctectomybusiness.industryRectal NeoplasmsCarcinomaRectumMultimodal therapyChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseTotal mesorectal excisionMagnetic Resonance ImagingNeoadjuvant TherapySurgeryRadiation therapy030220 oncology & carcinogenesisCase-Control StudiesPractice Guidelines as Topic030211 gastroenterology & hepatologySurgeryFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up StudiesJournal of the American College of Surgeons
researchProduct

Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation…

2017

Abstract Background Adjuvant chemotherapy is controversial in patients with locally advanced rectal cancer after preoperative chemoradiation. Valentini et al developed 3 nomograms (VN) to predict outcomes in these patients. The neoadjuvant rectal score (NAR) was developed after VN to predict survival. We aimed to validate these tools in a retrospective cohort at an academic institution. Patients and Methods VN and the NAR were applied to 158 consecutive patients with locally advanced rectal cancer treated with chemoradiation followed by surgery. According to the score, they were divided into low, intermediate, or high risk of relapse or death. For statistical analysis, we performed Kaplan-M…

AdultMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentRectal neoplasms prognosisLocally advancedUrologyKaplan-Meier EstimateRisk AssessmentAdjuvant; Chemotherapy; Rectal neoplasms prognosis; Oncology; GastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicinemedicineChemotherapyHumans030212 general & internal medicineAdjuvantSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overChemotherapyRectal NeoplasmsProportional hazards modelbusiness.industryHazard ratioGastroenterologyRetrospective cohort studyChemoradiotherapy AdjuvantMiddle AgedNomogrammedicine.diseaseNeoadjuvant TherapySurgeryNomogramsTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRisk assessmentbusinessClinical Colorectal Cancer
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

2021

BackgroundNo adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. MethodsWe conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks fo…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatment[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyB7-H1 AntigenDisease-Free Survival03 medical and health sciences0302 clinical medicineDouble-Blind MethodStomach NeoplasmsInternal medicineMedicine and Health SciencesmedicineCarcinomaHumans030212 general & internal medicineEsophagusImmune Checkpoint InhibitorsNeoadjuvant therapyAgedAged 80 and overChemotherapybusiness.industryCancerChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapyIntention to Treat Analysis3. Good healthNivolumabmedicine.anatomical_structureChemotherapy AdjuvantCarcinoma Squamous CellFemaleEsophagogastric JunctionNivolumabbusinessAdjuvantChemoradiotherapyNew England Journal of Medicine
researchProduct

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-dise…

2011

Background This trial was designed to prove superiority of irinotecan over etoposide combined with carboplatin in extensive-disease small-cell lung cancer. Patients and methods Patients were randomly assigned to receive carboplatin area under the curve 5 mg x min/ml either in combination with irinotecan 50 mg/m2 on days 1, 8, and 15 (IP) or etoposide 140 mg/m2 on days 1-3 (EP). Primary end point was progression-free survival (PFS) at 6 months. Secondary end points were overall survival (OS), response rate, and toxicity. Results Of 226 patients, 216 were eligible. Median PFS was 6.0 months [95% confidence interval (CI) 5.0-7.0] in the IP arm and 6.0 months (95% CI 5.2-6.8) in EP arm (P = 0.0…

AdultMalemedicine.medical_specialtyLung NeoplasmsMedizinIrinotecanGastroenterologyDisease-Free SurvivalCarboplatinchemistry.chemical_compoundInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicineHumansLung cancerEtoposideAgedEtoposideAged 80 and overbusiness.industryHazard ratioArea under the curveHematologyMiddle Agedmedicine.diseaseSmall Cell Lung CarcinomaCarboplatinConfidence intervalSurgeryIrinotecanOncologychemistryCamptothecinFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxa…

2010

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = …

AdultMalemedicine.medical_specialtyMultivariate analysisColorectal cancerSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalCapecitabineTreatment Outcome; Prognosis; Aged 80 and over; Male; Retrospective Studies; Randomized Controlled Trials as Topic; Middle Aged; Kaplan-Meier Estimate; Colorectal Neoplasms; Female; Disease-Free Survival; Humans; Quality of Life; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase III as Topic; Aged; Adult; Health Status Indicators; Multicenter Studies as TopicFolinic acidQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineOverall survivalHealth Status IndicatorsHumansMulticenter Studies as TopicClinical TrialsRadiology Nuclear Medicine and imagingneoplasmsmetastatic colorectal canceroxaliplatin physical functioning statusAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overbusiness.industryHematologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryOxaliplatinPhase III as TopicTreatment OutcomeClinical Trials Phase III as TopicOncologyQuartileQuality of LifeFemaleColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

2013

Objective To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non–muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy. Methods Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing 2 different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80 mg/50 mL) within 6 hours after TUR, followed by 5 more weekly instillations with (arm B) or without (arm A) monthly instillations for 1 year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariat…

AdultMalemedicine.medical_specialtyMultivariate analysisTime Factorsintravesical chemotherapy non-muscle invasive bladder cancerUrologymedicine.medical_treatmentcigarette smokingKaplan-Meier EstimateCystectomyGastroenterologyDisease-Free SurvivalSettore MED/24 - UrologiaCystectomyCigarette smokingRisk FactorsMulticenter trialInternal medicinemedicineCarcinomaHumansAgedEpirubicinProportional Hazards ModelsAged 80 and overAntibiotics AntineoplasticProportional hazards modelbusiness.industryCarcinomaSmokingMiddle AgedFormer Smokermedicine.diseaseintermediate-risk tumorrecurrence.Combined Modality TherapySurgeryUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessEpirubicinmedicine.drug
researchProduct

Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains i…

2009

In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment approaches, but survival benefits have not been confirmed in controlled studies. This retrospective study includes 176 consecutive patients younger than age 60 years in whom PMF was diagnosed during a 30-year period (1976-2005). Median age at diagnosis was 50 years (range, 18-59 years), and 98 patients (55%) were men. At the time of this report, 99 patients (56%) had died; the 77 surviving patients were followed up for a median of 8 years (range, 4-24 years). Overall median survival was 9.2 years, and 15- and 20-year survival rates were 32% and 20%, respectively. According to the Dupriez Prognosti…

AdultMalemedicine.medical_specialtyMultivariate analysisTransplantation ConditioningAdolescentmedicine.medical_treatmentDiseaseHematopoietic stem cell transplantationKaplan-Meier EstimateDisease-Free SurvivalSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalSurvival dataInternal medicinemedicineHumansMyelofibrosisSurvival rateProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelBrief ReportHematopoietic Stem Cell TransplantationRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUnited StatesSurgerySurvival RatePrimary MyelofibrosisMultivariate AnalysisFemalebusiness
researchProduct

Long-term results (7 to 10 years) of endoscopic papillotomy for choledocholithiasis. Multivariate analysis of prognostic factors for the recurrence o…

1998

Abstract Background: The long-term outcome after endoscopic papillotomy is poorly defined. The aim of this study was to determine the long-term results of this method in the treatment of common duct calculi and to determine which prognostic factors are associated with the relapse of biliary symptoms. Methods: Between 1985 and 1988, 223 consecutive (149 women, mean age 67.9 years) patients underwent endoscopic papillotomy for duct stones; 127 had already undergone cholecystectomy or underwent this operation during the same hospitalization. Follow-up data were obtained retrospectively from the patients and patients' relatives and general practitioners. Results: The procedure was successful in…

AdultMalemedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentGallstonesGastroenterologyDisease-Free SurvivalSphincterotomy EndoscopicPostoperative ComplicationsRecurrenceInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testBile ductbusiness.industryGallbladderGastroenterologyRetrospective cohort studyMiddle AgedPrognosisSurgeryEndoscopymedicine.anatomical_structureTreatment OutcomeBiliary tractMultivariate AnalysisCholecystectomyFemalebusinessDuct (anatomy)Follow-Up StudiesGastrointestinal endoscopy
researchProduct